Inogen, Inc $INGN Shares Acquired by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC increased its stake in Inogen, Inc by 35.7% in the first quarter, owning over 1 million shares valued at approximately $7.3 million.
• Inogen reported earnings of ($0.15) per share, exceeding expectations, with quarterly revenue of $92.28 million, above the analyst estimate of $90.40 million.
• Analysts have set a new price target of $12.00 for Inogen, reflecting a transition in rating from "hold" to "moderate buy" by Needham & Company LLC.

Acadian Asset Management LLC grew its holdings in Inogen, Inc (NASDAQ:INGN - Free Report) by 35.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,028,322 shares of the medical technology company's stock after purchasing an additional 270,453 shares during the quarter. Acadian Asset Management LLC owned about 3.82% of Inogen worth $7,325,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of Inogen during the 1st quarter valued at approximately $463,000. Goldman Sachs Group Inc. raised its position in shares of Inogen by 16.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,180 shares of the medical technology company's stock valued at $2,026,000 after buying an additional 41,002 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in shares of Inogen during the 1st quarter valued at approximately $85,000. AQR Capital Management LLC raised its position in shares of Inogen by 30.1% during the 1st quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company's stock valued at $4,022,000 after buying an additional 130,381 shares during the period. Finally, Cubist Systematic Strategies LLC raised its position in shares of Inogen by 1.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 124,993 shares of the medical technology company's stock valued at $891,000 after buying an additional 1,751 shares during the period. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Stock Performance

Shares of NASDAQ:INGN traded up $0.44 during trading on Thursday, hitting $8.76. The company's stock had a trading volume of 102,562 shares, compared to its average volume of 269,682. The business has a 50 day moving average price of $7.33 and a two-hundred day moving average price of $7.08. The company has a market capitalization of $236.87 million, a PE ratio of -8.26 and a beta of 1.78. Inogen, Inc has a fifty-two week low of $5.70 and a fifty-two week high of $12.91.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical technology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. The business had revenue of $92.28 million during the quarter, compared to the consensus estimate of $90.40 million. Inogen had a negative net margin of 7.58% and a negative return on equity of 13.77%. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts expect that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

INGN has been the topic of several analyst reports. Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price target on the stock in a research report on Thursday, May 22nd. B. Riley began coverage on shares of Inogen in a report on Monday, June 16th. They issued a "buy" rating and a $14.00 target price for the company. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $11.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.